Table 1.
Patient demographics.
| Characteristics | Daptomycin susceptibility | P-value | |
|---|---|---|---|
| Sensitive (%) | Resistant (%) | ||
| Total | 1299 (97.2) | 38 (2.8) | |
| Age | |||
| <65 | 632 (48.7) | 18 (47.4) | 0.876 |
| ≥65 | 667 (51.4) | 20 (52.6) | |
| Sex (male/female) | |||
| Male | 772 (59.4) | 24 (63.2) | 0.645 |
| Female | 527 (40.6) | 14 (36.8) | |
| Implantation, catheter | |||
| With | 223 (17.2) | 11 (28.9) | 0.060 |
| Without | 1076 (82.8) | 27 (71.1) | |
| Previous glycopeptide use | |||
| Yes | 305 (23.5) | 17 (44.7) | 0.003 |
| No | 994 (76.5) | 21 (55.3) | |
| Vancomycin susceptibility | |||
| MIC < 2 mg/L | 1016 (78.2) | 27 (71.1) | 0.293 |
| MIC ≥ 2 mg/L | 283 (21.8) | 11 (28.9) | |
| Teicoplanin susceptibility | |||
| MIC < 16 mg/L | 1212 (93.3) | 23 (60.5) | <0.0001* |
| MIC ≥ 16 mg/L | 87 (6.7) | 15 (39.5) | |
| Previous linezolid use | |||
| Yes | 29 (2.2) | 2 (5.3) | 0.219 |
| No | 1270 (97.8) | 36 (94.7) | |
| Previous daptomycin use | |||
| Yes | 91 (7.0) | 7 (18.4) | 0.018* |
| No | 1208 (93.0) | 31 (81.6) | |
| Previous penicillin use | |||
| Yes | 469 (36.1) | 21 (55.3) | 0.016 |
| No | 830 (63.9) | 17 (44.7) | |
| Previous cephem use | |||
| Yes | 863 (66.4) | 28 (73.7) | 0.350 |
| No | 436 (33.6) | 10 (26.3) | |
| Previous carbapenem use | |||
| Yes | 497 (38.3) | 22 (57.9) | 0.014 |
| No | 802 (61.7) | 16 (42.1) | |
| Previous aminoglycoside use | |||
| Yes | 97 (7.5) | 3 (7.9) | 0.921 |
| No | 1202 (92.5) | 35 (92.1) | |
| Previous tetracycline use | |||
| Yes | 68 (5.2) | 6 (15.8) | 0.016* |
| No | 1231 (94.8) | 32 (84.2) | |
| Previous fluoroquinolone use | |||
| Yes | 659 (50.7) | 24 (36.8) | 0.131 |
| No | 640 (49.3) | 14 (63.2) | |
| Previous sulfamethoxazole/trimethoprim use | |||
| Yes | 237 (18.2) | 7 (18.4) | 0.978 |
| No | 1062 (81.8) | 31 (81.6) | |
*The Fisher’s exact test.